CIK 0001439222 · Large accelerated filer
AGIOS PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- AGIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-649-8600
- Business address
- 88 SIDNEY STREET, CAMBRIDGE, MA, 02139
- Former names
- AGIOS PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $371,112
- in 2 filings, $371K under 10b5-1 plans
Net −$371,112. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-01 | Viswanadhan Krishnan Chief Corp Dev & Strategy | Grant or award · Stock options (right to buy) 10b5-1 | +52,000 | 52,000 | ||
| 2026-01-05 | Milanova Tsveta Chief Commercial Officer | Option exercise 10b5-1 | +8,475 | 37,665 | ||
| 2026-01-05 | Milanova Tsveta Chief Commercial Officer | Sale 10b5-1 | −2,872 | $27.02 | $78K | 34,793 |
| 2026-01-05 | Milanova Tsveta Chief Commercial Officer | Option exercise · Restricted stock units 10b5-1 | −8,475 | 0 | ||
| 2025-12-30 | Burns James William Chief Legal Officer | Option exercise 10b5-1 | +6,000 | 34,650 | ||
| 2025-12-30 | Burns James William Chief Legal Officer | Sale 10b5-1 | −2,932 | $27.09 | $79K | 31,718 |
| 2025-12-30 | Burns James William Chief Legal Officer | Option exercise · Performance share units 10b5-1 | −6,000 | 0 | ||
| 2025-12-30 | Goff Brian Chief Executive Officer | Option exercise 10b5-1 | +25,528 | 149,056 | ||
| 2025-12-30 | Goff Brian Chief Executive Officer | Sale 10b5-1 | −12,473 | $27.09 | $338K | 136,583 |
| 2025-12-30 | Goff Brian Chief Executive Officer | Option exercise 10b5-1 | +12,750 | 149,333 | ||
| 2025-12-30 | Goff Brian Chief Executive Officer | Sale 10b5-1 | −6,230 | $27.09 | $169K | 143,103 |
| 2025-12-30 | Goff Brian Chief Executive Officer | Option exercise · Performance share units 10b5-1 | −25,528 | 25,528 | ||
| 2025-12-30 | Goff Brian Chief Executive Officer | Option exercise · Performance share units 10b5-1 | −12,750 | 0 | ||
| 2025-12-30 | Gheuens Sarah Chief Medical Officer | Option exercise 10b5-1 | +6,000 | 67,727 | ||
| 2025-12-30 | Gheuens Sarah Chief Medical Officer | Sale 10b5-1 | −2,932 | $27.09 | $79K | 64,795 |
| 2025-12-30 | Gheuens Sarah Chief Medical Officer | Option exercise · Performance share units 10b5-1 | −6,000 | 0 | ||
| 2025-12-30 | Milanova Tsveta Chief Commercial Officer | Option exercise 10b5-1 | +6,000 | 32,122 | ||
| 2025-12-30 | Milanova Tsveta Chief Commercial Officer | Sale 10b5-1 | −2,932 | $27.09 | $79K | 29,190 |
| 2025-12-30 | Milanova Tsveta Chief Commercial Officer | Option exercise · Performance share units 10b5-1 | −6,000 | 0 | ||
| 2025-12-30 | Jones Cecilia Chief Financial Officer | Option exercise 10b5-1 | +6,000 | 40,326 |
Page 9 of 48 · 941 trades